In this video interview, Professor Jens Bedke, Professor of Urology and Vice Chairman at the Department of Urology, University Hospital Tuebingen, Germany, discusses the advances in first-line treatment of renal cell carcinoma (RCC) from monotherapy, which has been the standard of care for the treatment of RCC, to combination therapies.

First-line treatment with a combination of an immune checkpoint inhibitor and a tyrosine kinase inhibitor (TKI) has been shown to improve outcomes in patients with clear-cell metastatic RCC, as compared with the current standard of care.  Professor Bedke reviews the data and the impact on clinical practice in this interview with UroToday.

Watch the video interview on UroToday here